Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation

Chrystalleni Mylonas, Shifra T. Zwas, Galina Rotenberg, Gal Omry, Ohad Cohen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: To prevent the unwarranted effects of post-thyroidectomy hypothyroidism prior to radiodine (RAI) ablation, patients with well-differentiated thyroid cancer can currently undergo this treatment while in a euthyroid state. This is achieved with the use of recombinant human thyroid-stimulating hormone (rhTSH) injections prior to the ablation. objectives: To demonstrate the efficacy of rhTSH in radio-iodine thyroid ablation in patients with differentiated thyroid cancer. methods: We conducted a retrospective study of patients who underwent total thyroidectomy for well-differentiated thyroid cancer with different levels of risk, treated with rhTSH prior to remnant ablation with radioiodine. results: Seventeen patients with thyroid cancer were studied and followed for a median of 25 months (range 8-49 months). Ablation (defined as stimulated thyroglobulin < 1 mg/ml and negative neck ultrasonography) was successful in 15 patients (88.2%). One of the patients was lost to follow-up. conclusions: The use of rhTSH with postoperative radioiodine ablation may be an efficient tool for sufficient thyroid remnant ablation, avoiding hypothyroidal state in the management of thyroid cancer patients.

Original languageEnglish
Pages (from-to)106-109
Number of pages4
JournalIsrael Medical Association Journal
Issue number2
StatePublished - Feb 2014


  • Recombinant human thyroid-stimulating hormone (rhTSH)
  • Thyroid cancer
  • Thyroid remnant ablation


Dive into the research topics of 'Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation'. Together they form a unique fingerprint.

Cite this